



# ACE Fund 20 Annual Report

July 2020

@tcasandiego

#TCAtoday

# ACE Fund 20 Manager's Note

ACE Fund 20 is the latest of our TCA annual funds, which are designed to attract the best early stage investments while providing diversification in a low-cost fund for our investing members. Launched with \$3.7M in October 2019 (vs. \$2.2M in ACE 19), ACE 20 invested in 19 companies over 9 months across verticals including medical devices, cleantech, SaaS, agtech, digital health and drug development. Compared with ACE 19, the greatest thematic trend was a focus on digital health, with 5 healthtech software companies and 2 connected devices included among the ACE 20 portfolio.

The investment frequency was lumpy, with 3 months – November 2019, February 2020 and March 2020 – accounting for \$2.4M of the Fund's total capital, including the first (and only) \$500K ACE Annual Fund investment to date: iDental. Another trend observed in ACE 20 was the continued broadening of TCA's geographic scope; 42% of companies were based outside Southern California (compared to 30% in ACE 19), and 70% were led by other investors outside of TCA (compared to 50% in ACE 19). Post-money valuations (and convertible note caps) ranged widely from \$4M to \$42M (similar to ACE 19).

We are encouraged by the quality and diversity of the 19 companies in ACE Fund 20, and are confident that our annual Fund model provides an efficient and compelling approach for our investor-members to fully participate in this exciting asset class. We thank you for joining us!

- Dean Rosenberg, Fund Manager
- Ashok Kamal, TCA-SD Executive Director



# Portfolio Investments

- Holdings

Portfolio Value	\$3,656,982
Companies/Funds	19
Rounds	19


- Portfolio Returns Since Inception

IRR if Liquidated at Current Valuation	-
Total Cash Invested	\$3,656,982
Total Cash Returned	\$0
Combined Exit Multiple	-
Cumulative IRR from all Exits	-



# Value by Entity

## Percentage of Fund Investment by Entity




Entity	Investment
Deep Blue Medical Advances, Inc.	\$99,997
Visgenx	\$100,000
Mercato	\$300,000
Discover Echo	\$300,000
Heart Health Intelligence	\$300,000
Aligned Carbon	\$100,000
Eyedaptic	\$100,000
BlueNalu	\$199,985
iDental	\$500,000
Blackdot	\$100,000
Habitu8	\$200,000
Upcycle	\$300,000
Strategikon Pharma	\$200,000
Labviva	\$200,000
Insight Medical Systems	\$100,000
Gali Health	\$200,000
Noria Water Technologies	\$100,000
Maxwell Biomedical	\$200,000
Abintus Bio	\$57,000
<b>Total Investment</b>	<b>\$3,656,982</b>



# Investments by Date

## Investments By Month



Entity	Amount	Date
Deep Blue Medical Advances, Inc.	\$99,997	October 14, 2019
Visgenx	\$100,000	October 15, 2019
Mercato	\$300,000	November 18, 2019
Discover Echo	\$300,000	November 22, 2019
Heart Health Intelligence	\$300,000	November 29, 2019
Aligned Carbon	\$100,000	January 28, 2020
Eyedaptic	\$100,000	January 29, 2020
BlueNalu	\$199,985	February 4, 2020
iDental	\$500,000	February 7, 2020
Blackdot	\$100,000	February 20, 2020
Habitu8	\$200,000	March 16, 2020
Upcycle	\$300,000	March 16, 2020
Strategikon Pharma	\$200,000	March 18, 2020
Labviva	\$200,000	April 2, 2020
Insight Medical Systems	\$100,000	April 14, 2020
Gali Health	\$200,000	April 17, 2020
Noria Water Technologies	\$100,000	June 10, 2020
Maxwell Biomedical	\$200,000	June 11, 2020
Abintus Bio	\$57,000	June 12, 2020

Year	Invested
2019	\$1,099,997
2020	\$2,556,985



# Summary of ACE Fund 20 Results

- \$3.75M capital raised from 164 members (3% reserved for expenses)
- 19 investments
  - iDental = \$500K
  - Mercato, Discover Echo, Heart Health Intelligence, Upcycle = \$300K
  - BlueNalu, Habitu8, Strategikon Pharma, Labviva, Gali Health, Maxwell Biomedical = \$200K
  - Deep Blue Medical Advances, Visgenx, Aligned Carbon, Eyedaptic, Blackdot, Insight Medical Systems, Noria Water Technologies = \$100K
  - Abintus Bio = \$57K
  - 13 Life Science (5 digital health), 6 Tech
  - 7 San Diego, 4 SoCal, 4 Bay Area, 4 Non-CA
  - < 3% of reviewed deals were funded



# Deep Blue Medical Advances, Inc.



Deep Blue Medical Advances is a surgical innovations company developing a novel hernia mesh to address the high rate of hernia occurrence and recurrence. Millions of hernia surgeries are done globally with billions of dollars in clinical cost; Deep Blue's T-Line Hernia Mesh, with integral suture-like extensions, is designed to eliminate a key point of failure for conventional mesh fixation - the mesh/suture/tissue interface - and to provide superior anchor strength (up to 2.75x), advanced mesh tension adjustment, and the ability to use less mesh.

In addition, their Anchor Clip fixation device design enables faster, stronger, easier mesh implantation. Deep Blue products enhance hernia surgery with a potentially significant impact on the \$1.1B global hernia device market. T-Line Hernia Mesh has the potential to reduce hernia occurrence and recurrence by preventing or reducing mesh fixation failure.

Domains	Life Science, Medical Devices
Location	Durham, NC
Founded	2015
Operating Status	Active
Number of Employees	9
Round	Series A Preferred
Commitment	\$99,997
Shares	18,931
Price	\$5.28210
Valuation Date	10/17/19
Cost Basis	\$99,997
Value	\$99,997
Unrealized IRR	-



# Visgenx



Visgenx is developing a therapeutic for Age-Related Macular Degeneration (AMD), the leading cause of irreversible blindness, which has no approved treatment. AMD affects more than 11 million in the US and 196 million worldwide. Visgenx targets a severe form of macular degeneration known as “Geographic Atrophy” (GA).

Current therapies do not address ARMD or “dry” AMD, and only address the smaller subset of macular degeneration known as “wet AMD.” Visgenx’s science is licensed from research conducted at the Shiley Eye Institute at UCSD, identifying the age-related dysfunction of the ELOVL2 gene. Their therapeutic drug injection reverses gene dysfunction through demethylation, which has improved scotopic response in functional knock-out mice test subjects.

Domains	Biotech, Therapeutics
Location	San Diego, CA
Founded	2018
Operating Status	Active
Number of Employees	11

Round	Convertible Promissory Note
Commitment	\$100,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$100,000
Value	\$100,000
Unrealized IRR	-





# Mercato



Mercato is a SaaS platform for independent and specialty grocers, merchants, and artisans to offer the same level of local customer service and delivery offered by large chain supermarkets.

Locally owned and operated markets are often superior to conglomerates and national chain brands: with an emphasis on quality foods, customized product offerings that serve the needs and preferences of their specific customer base rather than a one-size-fits-all approach, and superior service offered by owners that are stakeholders in the local community, customers prefer shopping locally when possible.

Mercato bridges the resource gap between local grocers and their chain competitors, offering e-commerce services such as product catalog creation, POS integration, online ordering, customized marketing, delivery (through partnership with popular third-party delivery services), pricing assistance, inventory tracking, and customer service.

Domains	E-Commerce, Food Tech
Location	San Diego, CA
Founded	2015
Operating Status	Active
Number of Employees	11-50

Round	Series Seed II
Commitment	\$300,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$300,000
Value	\$300,000
Unrealized IRR	-



# Discover Echo



Echo, formerly Echo Laboratories, is setting a new precedent in microscope usability and design. Their hybrid microscope, Revolve, was the world's first Hybrid Microscope that transforms between Upright and Inverted configurations, eliminating the need for two separate instruments. Eyepieces are replaced with an iPad tablet to view and capture images with ease. Echo's software app simplifies the workflow of acquiring, sharing, and analyzing images, delivering a modern, seamless approach to data management and hardware integration.

Echo has had \$25 million in sales since winning TCA's Quick Pitch competition in 2016, and is preparing to launch two new microscopes, Hyperscope and Revolution, in 2020.

Domains	Diagnostics, Biotech
Location	San Diego, CA
Founded	2014
Operating Status	Active
Number of Employees	45

Round	Convertible Note
Commitment	\$300,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$300,000
Value	\$300,000
Unrealized IRR	-



# Heart Health Intelligence



Heart Health Intelligence has designed and developed The Heart Seat, a unique cloud-connected toilet seat-based platform that captures clinical-grade and relevant cardiac data from the patient's home, without any change in the user's habits. With built in ECG, PPG, and BCG capabilities, it allows remote passive daily monitoring of heart rate, blood pressure, body weight, blood oxygen, impedance (fluid retention), pulmonary artery pressure, QRS duration, QTc interval, arrhythmias, and cardiac output / stroke volume, in one simple solution that patients don't need to go out of their way to use, ensuring patient adherence.

The Heart Seat has tested its cardiac measures in over 300 subjects in partnership with University of Rochester Medical Center. The Heart Seat has the potential to improve the quality of life for patients by allowing them to track health changes in the comfort of their own homes without the need to change their behavior.

Domains	Diagnostics, Life Science
Location	Rochester, NY
Founded	2018
Operating Status	Active
Number of Employees	1-10

Round	Series Seed Preferred
Commitment	\$300,000
Shares	240,110
Price	\$1.24943
Valuation Date	11/29/2019
Cost Basis	\$300,000
Value	\$300,000
Unrealized IRR	-



# Aligned Carbon



Founded and led by two Stanford scientists, Aligned Carbon manufactures wafer-scale arrays of aligned carbon nanotubes (CNTs) to the exacting standards of integrated circuit foundries.

Aligned Carbon can purify the CNT populations they synthesize to be entirely semiconducting or entirely metallic, opening a range of applications by addressing a key problem in a \$500B market. These applications include CNT-Si hybrid monolithically integrated (stacked 3D) processors, which will be 1000x faster and more efficient than current single-layer processors, and RF data transmission circuitry, which can enable performance beyond 5G.

Aligned Carbon delivers a unique foundry ready CNT material, and will grow the company through material sales as well as peripheral equipment and process capabilities to meet the market's demands. Their 3D integrated circuit processors will be particularly disruptive to AI and other intensive computing fields.

Domains	Advanced Materials, Manufacturing
Location	Santa Clara, CA
Founded	2018
Operating Status	Active
Number of Employees	0-5
Round	Series Seed
Commitment	\$100,000
Shares	153,846
Price	\$0.65
Valuation Date	01/28/2020
Cost Basis	\$100,000
Value	\$100,000
Unrealized IRR	-



# Eyedaptic



Eyedaptic has developed an AR (Augmented Reality) vision assistance device for Age-Related Macular Degeneration (AMD) patients. Most vision assistance products on the market today only offer magnification, leaving the limited field of view unaddressed.

Eyedaptic uses simulated natural vision software in their EYE2 to optimize peripheral vision, enabling viewing of the entire field of view (FOV) through reprojection of the content of the center of a user's natural FOV into their peripheral vision. EYE2 is a non-invasive visual assistive AR-based smart eyewear device in the form-factor of a pair of glasses, customizable and adaptive to a user's vision automatically through their proprietary software.

EYE2 allows users to regain freedom and move about easily without restrictions as a hands-free, easy-to-wear design, providing an improved quality of life. Eyedaptic won second place in TCA's Quick Pitch competition in 2019.

Domains	Medical Devices, Augmented Reality
Location	Laguna Niguel, CA
Founded	2016
Operating Status	Active
Number of Employees	0-5
Round	Seed II
Commitment	\$100,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$100,000
Value	\$100,000
Unrealized IRR	-



# BlueNalu



Providing healthy, safe, and trusted seafood products that support sustainability and diversity of our oceans. BlueNalu has overcome technical and business hurdles to become a pioneer in “cellular aquaculture” – a platform technology in which living cells isolated from fish tissue are placed into culture media for cellular proliferation – growing great-tasting fresh and frozen seafood products it can market as alternative proteins. BlueNalu’s seafood products are designed to be as nutritious as conventional seafood, produced in a way that is healthier for people, promotes humane treatment of animals, and ensures sustainability and ecological protection.

BlueNalu is especially focused on species that are over-fished, heavily imported, or difficult to farm – allowing a reduction in fisheries and foreign imports while creating local jobs and enhancing food security. BlueNalu is also able to avoid the use of genetic modification, antibiotics, or fetal bovine serum in their aquaculture – while remaining free of mercury and other environmental contaminants.

Domains	Biotech, Food Tech
Location	San Diego, CA
Founded	2017
Operating Status	Active
Number of Employees	1-10

Round	Series A
Commitment	\$199,985
Shares	10,810
Price	\$18.50
Valuation Date	-
Cost Basis	\$199,985
Value	\$199,985
Unrealized IRR	-



# iDental

## iDENTICAL

iDental utilizes 3D technology to make drill-free dental implants. After a tooth extraction, iDental creates a 3D model of the tooth root, applies proprietary design features to it and then uses that model to manufacture the implant. Within a week of the extraction, the dentist inserts the implant in the patient's socket site without drilling or chance of misplacement.

Dental implants today utilize a 50-year-old drill-and-screw technology that is highly invasive, lengthy and expensive, and it's only offered by dental specialists and 1 in 10 dentists. The current procedure involves drilling a hole into the patient's jawbone, which can cause nerve damage, takes 7-10 months to complete and costs up to \$6,000 per tooth, making dental implants inaccessible to people who need them.

iDental provides the dentist with a low-risk, high-margin revenue stream that requires minimal training, no capital investment and meaningful differentiation for their dental practice.

Domains	Life Science, Medical Devices
Location	Walnut Creek, CA
Founded	2018
Operating Status	Active
Number of Employees	2
Round	Seed
Commitment	\$500,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$500,000
Value	\$500,000
Unrealized IRR	-



# Blackdot

# blackdot

Blackdot is building the first automatic tattoo machine. Aiming to revolutionize the tattoo experience for consumers, artists, and stores, Blackdot has several innovations in development, including an online tattoo marketplace where consumers can purchase designs from top artists around the world (including limited edition, unique one-off designs, and celebrity tattoos), temporary and less painful tattoos, quick sessions and perfectly replicable designs.

Artist income would no longer be tied to the number of hours they can physically tattoo in a specific location; shops would be able to increase customers per day and potentially expand to a franchise model. Brands could utilize temporary tattoos for advertisements and viral exposure. Customers would have massively increased selection and quality from top artists – on demand, less painfully with temporary options. Machines could be placed in mainstream stores creating safer locations, more visibility, luxury tattoo experiences. Blackdot is scheduled to open its pilot boutique in Austin, TX in 2020.

Domains	Consumer, Hardware
Location	Austin, TX
Founded	2019
Operating Status	Active
Number of Employees	1

Round	SAFE
Commitment	\$100,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$100,000
Value	\$100,000
Unrealized IRR	-





# Habitu8



Habitu8 is a cybersecurity provider that tackles the problem of cybersecurity at what may be the weakest point – a company’s own employees ignorance of security principles.

Their first method is through live-action training videos (“Hashtag Awareness”) filmed with high production value and using humor to instill their messaging more effectively.

Their second method is their Learning Management Simplified (LMS) platform, which allows a more engaging method of having employees meet compliance requirements, with bespoke Netflix-style videos combined with tracking and reporting features to ensure employees view all the security protocol lessons required.

Domains	Cybersecurity, SaaS
Location	Torrance, CA
Founded	2017
Operating Status	Active
Number of Employees	1-10

Round	Seed Extension
Commitment	\$200,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$200,000
Value	\$200,000
Unrealized IRR	-



# Upcycle & Company



Upcycle & Co's Native Soil Fertilizer is a sustainable natural fertilizer made of local, naturally sourced organic matter.

Carbon, an essential component of healthy soil, is rarely included in commercially available fertilizers. Carbon is rapidly oxidized in arid climates such as the Southwestern United States and must be routinely replenished to maintain adequate levels for soil health. Organic matter affects the chemical and physical properties of soil and its overall health. Its composition and breakdown rate affect soil structure, porosity, moisture holding capacity, biological diversity, and nutrient availability. Native Soil Fertilizer incorporates the macronutrients contained in commercial fertilizers into a biologically derived carbon matrix and adds naturally occurring organic matter, saving money by reducing the number of fertilizer applications every year, building soil structure, reducing water usage, labor and O&M costs, and minimizing runoff and water pollution.

Domains	Agtech, Consumer
Location	San Diego, CA
Founded	2015
Operating Status	Active
Number of Employees	1-10

Round	Seed
Commitment	\$300,000
Shares	1,253,133
Price	\$0.23940
Valuation Date	3/18/20
Cost Basis	\$300,000
Value	\$300,000
Unrealized IRR	-



# Strategikon Pharma (Clinical Maestro)



Strategikon Pharma's Clinical Maestro is a software platform designed for clinical study planning, serving to increase the efficiency and accuracy of planning, sourcing, modeling, contract and financial management.

Pharma struggles with labor intensive manual processes leading to heavy staff infrastructures, workflow siloes and inefficiencies across the entire spectrum of clinical development. It usually takes multiple people to manage the non-operational aspects of clinical trial conduct and requires highly specialized expertise across finance and clinical ops.

Clinical Maestro is composed of two mirrored platforms, one targeting Pharma/Biotech companies ("Pharma Edition) and the other clinical study service providers to whom biopharma companies outsource clinical development ("Provider Edition"). The two platforms consist of multiple modular applications (e.g. planning, budgeting, RFP creation, etc.) which can be deployed individually or seamlessly interconnected to enable highly efficient management of the clinical business.

Domains	Biotech, SaaS
Location	San Rafael, CA
Founded	2017
Operating Status	Active
Number of Employees	5-10

Round	Series Seed Preferred Stock
Commitment	\$200,000
Shares	276,625
Price	\$0.72300
Valuation Date	03/18/2020
Cost Basis	\$200,000
Value	\$200,000
Unrealized IRR	-



# Labviva



Labviva's AI-based technology platform serves the buyers and suppliers in the \$60B Life Science market by providing flexible tools with the ability to serve enriched scientific product catalog content from multiple suppliers in meaningful taxonomies that is valuable to researchers and purchasing professionals.

Labviva seamlessly integrates with its client's eProcurement platforms and enables purchasing departments to take control of their supply chain. Through greater visibility of purchasing trends, deep and insightful analytics and highly efficient onboarding of the tail spend, Labviva is providing its clients with significant cost savings. Two target markets are procurement professionals (focusing on ease of integration with buyer's purchasing platforms, ease of onboarding of the tail spend suppliers and comprehensive purchasing analytics) and scientific staff (comprehensive product data, contextual representation of products in research applications, and availability of supporting scientific literature to inform their decision making process).

Domains	Life Science, SaaS
Location	Cambridge, MA
Founded	2017
Operating Status	Active
Number of Employees	5-10

Round	Seed
Commitment	\$200,000
Shares	377,929
Price	\$0.5292
Valuation Date	04/02/2020
Cost Basis	\$200,000
Value	\$200,000
Unrealized IRR	-



# Insight Medical Systems



Insight Medical Systems is developing ARVIS (Augmented Reality Visualization and Information System). ARVIS combines tracking cameras with a 3D display and handsfree interface in a standalone surgical headset. The system, which includes a single tray of trackable instruments, provides the surgeon with key alignment and positioning data without the need for preoperative imaging or external equipment. ARVIS is worn and controlled by the surgeon, tracks from the surgeon's viewpoint, and delivers information to the surgeon right at the point of care.

The current standard is for surgeons to use guides or other external devices to assist in performing procedures, leading to inconsistent results and risking worse outcomes, longer operative times, litigation, and the need for expensive revision surgery. Current surgical robots and navigation systems increase accuracy and reproducibility of hip and knee replacement procedures but add cost, complexity and operative time. ARVIS has comparable accuracy but is faster and less expensive than robotic systems.

Domains	Augmented Reality, Medical Devices
Location	Laguna Hills, CA
Founded	2016
Operating Status	Active
Number of Employees	1-10
Round	Seed
Commitment	\$100,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$100,000
Value	\$100,000
Unrealized IRR	-



# Gali Health



Gali is working to create personalized medical solutions for sufferers of chronic conditions through a pioneering combination of app-based patient surveying and population-scale analysis of genomic, lifestyle, and health backgrounds.

Currently focusing on inflammatory bowel diseases (IBD) such as Crohn's and Colitis, Gali aims to provide users with AI-assisted personalized disease self-management through their app, providing support for medical, psychological, and lifestyle issues through a combination of analysis of self-reported and collective user trends, the latest information from healthcare professionals and researchers, and genomic data provided by users and other databases. With tens of thousands of users, Gali will have the largest sample-size of IBD sufferers in history, and will be able to leverage massive synergetic data sets with common lifestyle, diet, genetic and historical health backgrounds to recommend effective treatments and management techniques for users with similar data points, as well as being able to contribute to medical and pharmaceutical research.

Domains	Consumer Mobile, Biotech
Location	San Francisco, CA
Founded	2016
Operating Status	Active
Number of Employees	11-50

Round	Seed Extension
Commitment	\$200,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$200,000
Value	\$200,000
Unrealized IRR	-



# Noria Water Technologies



Noria Water Technologies specializes in Reverse Osmosis (RO) membrane optimization through their RO-Spotlight system. Fouling and mineral scaling place limits on the service lifetimes of membranes. As membranes may be used in sensitive, mission-critical, or health-related environments, companies must err on the side of caution and are often conservatively discarding viable membranes years before they need to be replaced. Noria can cut operating costs by 30% by simply allowing more efficient use of membrane technology, allowing facilities to scale back chemical usage, cleaning procedures with detrimental higher system pressure, allowing for easier stress testing and early failure detection, and reducing energy usage and overall downtime.

Used in advanced water treatment facilities such as wastewater recycling, desalination, and agricultural/food/beverage processing, Noria also has massive potential for industrial usage in mining, semiconductors, petrochemical and pharmaceutical applications.

Domains	Cleantech, Industrial
Location	Los Angeles, CA
Founded	2014
Operating Status	Active
Number of Employees	3

Round	Seed
Commitment	\$100,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$100,000
Value	\$100,000
Unrealized IRR	-



# Maxwell Biomedical



Maxwell Biomedical is in the 5th generation of development of a wireless, battery-less micro-pacing system implanted device approach to pace atrial fibrillation (aFib) patients back to normal sinus rhythm.

Atrial fibrillation is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. Current treatments are either ineffective toxic drugs, or ablation procedures (with a 50% failure rate after 1 year). A micro-pacing system is more effective, but none have been able to work painlessly before now.

Maxwell's micro-pacing system is made up of a micro-flexible PCB and an antenna on a stent-like anchor delivered into the Vein of Marshal (VoM). A handheld device serves as the wireless power supply and performs patient monitoring and AF detection. Maxwell will target persistent (24/7) aFib patients as well as those with failed ablation procedures.

Domains	Medical Devices
Location	San Diego, CA
Founded	2018
Operating Status	Active
Number of Employees	3

Round	Seed
Commitment	\$200,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$200,000
Value	\$200,000
Unrealized IRR	-





# Abintus Bio



Abintus is advancing 3rd generation in vivo chimeric antigen receptor T cells (“CAR-T”) products that may be administered directly to patients for treating cancer. This approach has the potential to address many of the current scientific and commercial challenges faced by companies with ex vivo CAR-T product and technology platforms. By comparison, 1st generation autologous CAR-T and 2nd generation allogeneic CAR-T are ex vivo procedures that modify cells outside their native environment, have high COGS and face challenges with scalability and patient access.

Based on highly customizable retroviral non-replicating vectors, Abintus is developing its lead investigational product candidate, RNV-CD19CAR, for the treatment of blood cancers such as lymphoma. Having products that may ultimately be available in an out-patient setting will provide greater patient access to potentially life saving treatments and provide a solution so that hospitals no longer lose money via inadequate NTAP reimbursement.

Domains	Biotech, Gene Therapy
Location	Encinitas, CA
Founded	2020
Operating Status	Active
Number of Employees	5

Round	Series Seed
Commitment	\$57,000
Shares	-
Price	-
Valuation Date	-
Cost Basis	\$57,000
Value	\$57,000
Unrealized IRR	-

